Vol 88, No 2 (2012)

The article presents results of the molecular typing and phylogenetic analysis of N. Gonorrhoeae strains in the Russian Federation conducted based on a large sample of N. Gonorrhoeae strains. A considerable genetic variety of N. Gonorrhoeae strains circulating in the territory of the Russian Federation was revealed, which can serve as an evidence of a high rate of accumulation of por and tbp gene mutations among the Russian population of N. Gonorrhoeae strains. The authors established the genetic relationship between individual sequence types of N. Gonorrhoeae strains, and revealed total and dominating sequence types of N. Gonorrhoeae strains found both in different territories of the Russian Federation and abroad, which confirms that such strains can be transferred between different territories of the Russian Federation and from abroad due to active migration of population.

Psoriasis is an autoimmune skin disease substantially reducing the patients’ quality of life. Practical application of biologic drugs made it possible to achieve substantial progress in the psoriasis therapy. Goal of the article: comparative evaluation of the efficacy of etanercept, infliximab, adalimumab and ustekinumab costs in psoriatic patients. Methods. The cost efficacy was evaluated based on the results of randomized placebo-controlled studies. The analysis was conducted by the cost/efficiency method from the point of view of the health care system. Reduction in the severity of the disease by the PASI index vs. baseline was used as a criterion to evaluate the clinical efficacy. The evaluation was carried out for a course of therapy lasting for 52 weeks; the analysis took into consideration data on all patients (both responding and not responding to the treatment in 12 weeks) as well as patients failing to respond to the treatment in 12 weeks and withdrawing from the therapy. Costs and clinical efficacy were assessed for the time period equal to one year. The costs per one patient achieving PASI 75 were taken as the cost/efficacy coefficient. Results: treatment with adalimumab was shown to be characterized by a lower cost/efficacy coefficient vs. etanercept; infliximab or ustekinumab. Withdrawal in case of non-responding patients in 12 weeks reduces the therapy costs by 17%—40%. In this case, adalimumab proves to be more cost efficient. Conclusions. Treatment of psoriatic patients with adalimumab is expedient from the clinical and economic points of view since it is characterized by the minimum cost/efficacy ratio against the background of high clinical efficacy vs. etanercept; infliximab or ustekinumab.

Doctors from the State Research Center for Dermatology, Venereology and Cosmetology followed up a female patient with a rare diagnosis: angiolymphoid hyperplasia with eosinophilia. The clinical nature of the skin had a number of specific features: propagation of eruptions all over the skin as well as double-side scrotal lymphadenopathy. The count of eosinophils in the total blood count was normal, which complicated the diagnostics. The authors provide data from literature sources on the etiology and pathogenesis, clinical features, differential diagnostics methods and therapy of the disease.

The authors examined the efficacy and safety of treatment of patients suffering from moderate to severe forms of psoriasis with ustekinumab (blocker of р40 subunit of interleukin-12 and interleukin-23) taking into account the PASi index. They revealed high clinical efficacy of ustekinumab for treatment of psoriatic patients.

Goal: evaluation of the efficacy and safety of acnecutan in patients with severe forms of acne or if other acne treatment methods prove to be inefficient. Materials and methods: the study involved 35 patients with severe forms of acne and acne resistant to other therapies. The patients received a monotherapy with acnecutan. The efficacy and safety of this therapy were evaluated at each visit judging by the clinical picture of the disease; the severity of the disease was defined based on the count of components (such as comedones, papulopustules, nodes, dyschromias and scars). The safety of the drug was assessed based on the data on adverse and unforeseen events taking into account subjective (patient’s complaints) and objective (total blood count, urine test, blood biochemistry) indices. Results: against the background of the course of treatment with acnecutan, all patients who participated in the study clinical achieved remission. Conclusion: acnecutan is a highly efficient drug for the treatment of severe forms of acne or acne resistant to other treatments.

Goal: to evaluate the clinical efficacy of 0.1% Protopic ointment in the treatment of atopic dermatitis as a part of a complex therapy. Materials and methods. The study involved a group of 30 patients of both sexes who were diagnosed with atopic dermatitis in the moderate and severe forms at the age of 17—40, who received the 0.1% Tacrolimus ointment (which was applied on the affection foci) as a part of a complex therapy twice a day. The efficacy and safety of this therapy were evaluated based on the SCORAD, Dermatology Life Quality Index (DLQI), indices of personal and situational anxiety, and subjective patient’s feelings. Results. The application of the Protopic ointment resulted in a high total percentage of clinical recovery and significant improvement (86.2%) as well as fast (on Day 7) achievement of a positive effect. Conclusion. The Protopic ointment is characterized by high efficacy and good tolerance when used for the treatment of moderate to severe forms of atopic dermatitis as a part of the complex therapy.

The article covers problems of vegetovascular changes in case of rosacea. The efficacy and safety of skin care products for rosacea patients were evaluated.

Calendar